MBD3L5 Inhibitors

The chemical class of MBD3L5 inhibitors encompasses compounds that impede the functional activity of the MBD3L5 protein. MBD3L5's role involves binding to methylated DNA; therefore, agents that alter DNA methylation patterns can modulate the protein's activity. For example, 5-Azacytidine, a nucleoside analog of cytidine, can be incorporated into DNA during replication and RNA during transcription, which leads to the inhibition of DNA methyltransferases and subsequent DNA demethylation. This reduction in DNA methylation levels can result in decreased binding of MBD3L5 to DNA, thereby inhibiting its activity. Similarly, RG108, a non-nucleoside inhibitor, directly targets DNA methyltransferases, preventing the methylation of cytosines within the DNA molecule. This inhibition of DNA methylation diminishes the methylated DNA substrate available for MBD3L5, leading to a functional decrease in the protein's activity.

Other compounds, such as procaine and hydralazine, although not initially developed as DNA methylation modifiers, have been observed to possess DNA demethylating activities. Procaine, by interfering with DNA methylation, can affect the epigenetic regulation of gene expression, which includes reducing the binding affinity of MBD3L5 to methylated DNA.